Diabetic retinopathy (DR) is a prevalent microvascular complication of diabetes mellitus (DM, both types 1 and 2), affecting millions of individuals worldwide. DM is known to induce changes in platelet function and hemostasis, thereby elevating the risk of thrombotic incidents. The hyperglycemic environment in DM can trigger platelet hyperactivity, potentially exacerbating the onset and progression of DR. Despite the intricate pathophysiology of DR, which involves oxidative stress, inflammation, retinal neovascularization, and the disruption of the blood-retina barrier, the specific mechanisms underlying platelet hyperactivity in the microvasculature of DM patients remain inadequately explored. Antiplatelet and anticoagulation medications have proven beneficial in preventing macrothombosis events in patients with DM. Further understanding of their therapeutic and prophylactic effects on DR could improve the understanding of underlying mechanisms and the treatment of not only DR, but other microvascular complications.
Original languageAmerican English
StatePublished - Jan 18 2024


Dive into the research topics of 'The potential beneficial role of anti-platelet/anti-coagulant medications on diabetic retinopathy: A Scoping Review Protocol'. Together they form a unique fingerprint.

Cite this